The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?

Medical Hypotheses

Volumn 70, Issue 6, 2008, Pages 1186-1192

  Har Noy, M ^a,b   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Immunovative Therapies Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; ORGAN DONOR; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TH1 CELL;

BONE MARROW TRANSPLANTATION; CD40 LIGAND; GRAFT VS HOST DISEASE; HUMANS; MODELS, IMMUNOLOGICAL; NEOPLASMS; STEM CELL TRANSPLANTATION; TH1 CELLS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 42949091026     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.10.008     Document Type: Article

References (56)

1. Fowler D.H. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 57 (2006) 225-244
2. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300 (1979) 1068-1073
3. Sullivan K.M., Storb R., Buckner C.D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320 (1989) 828-834
4. Kernan N.A., Collins N.H., Juliano L., Cartagena T., Dupont B., and O'Reilly R.J. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-vs.-host disease. Blood 68 (1986) 770-773
5. Ferrara J.L., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 (1991) 667-674
6. Harlin H., Artz A.S., Mahowald M., et al. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant 33 (2004) 491-497
7. Rezvani K., Yong A.S., Savani B.N., et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood (2007)
8. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
9. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267-296
10. Fowler D.H., Breglio J., Nagel G., Hirose C., and Gress R.E. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant 2 (1996) 118-125
11. Bertz H., Illerhaus G., Veelken H., and Finke J. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 13 (2002) 135-139
12. Dann E.J., Daugherty C.K., and Larson R.A. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 20 (1997) 369-374
13. Lee C.K., Lie A.K., Liang R., et al. Outcome of Chinese patients with chronic myeloid leukemia (CML) underwent allogeneic bone-marrow transplantation (BMT). Am J Hematol 61 (1999) 85-89
14. Childs R., and Barrett J. Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. Semin Hematol 39 (2002) 63-71
15. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343 (2000) 750-758
16. Eibl B., Schwaighofer H., Nachbaur D., et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88 (1996) 1501-1508
17. Yang Y.G., and Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Leuk Lymphoma 33 (1999) 409-420
18. Zhou J., Ye F., Chen H., Lv W., and Gan N. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 35 (2007) 290-300
19. Ikeda H., Chamoto K., Tsuji T., et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95 (2004) 697-703
20. Ferrara J.L., Abhyankar S., and Gilliland D.G. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc 25 (1993) 1216-1217
21. Antin J.H., and Ferrara J.L. Cytokine dysregulation and acute graft-versus-host disease. Blood 80 (1992) 2964-2968
22. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8 (2003) 223-246
23. Dey B.R., McAfee S., Colby C., et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and anti-tumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 9 (2003) 320-329
24. Rubio M.T., Kim Y.M., Sachs T., Mapara M., Zhao G., and Sykes M. Anti-tumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood 102 (2003) 2300-2307
25. Kraus A.B., Shaffer J., Toh H.C., et al. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 31 (2003) 609-621
26. Rubio M.T., Saito T.I., Kattleman K., Zhao G., Buchli J., and Sykes M. Mechanisms of the anti-tumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells. J Immunol 175 (2005) 665-676
27. Rubio M.T., Zhao G., Buchli J., Chittenden M., and Sykes M. Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning. Clin Immunol 120 (2006) 33-44
28. Saito T.I., Rubio M.T., and Sykes M. Clinical relevance of recipient leukocyte infusion as anti-tumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation. Exp Hematol 34 (2006) 1271-1277
29. Sykes M., Sheard M.A., and Sachs D.H. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 168 (1988) 2391-2396
30. Yang Y.G., Qi J., Wang M.G., and Sykes M. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood 99 (2002) 4207-4215
31. Ferrara J., Cooke K.R., and Teshma T. The pathophysiology of graft-vs.-host disease. In: Deeg J.F.A.C. (Ed). Graft-vs.-Host Disease (2005), Marcel Dekker, New York, NY 1-34
32. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
33. Hoebe K., Janssen E., and Beutler B. The interface between innate and adaptive immunity. Nat Immunol 5 (2004) 971-974
34. Snijders A., Kalinski P., Hilkens C.M., and Kapsenberg M.L. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10 (1998) 1593-1598
35. Hami L.S., Green C., Leshinsky N., Markham E., Miller K., and Craig S. GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy 6 (2004) 554-562
36. Koguchi Y., Thauland T.J., Slifka M.K., and Parker D.C. Preformed CD40 ligand exists in secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on the cell surface in an antigen specific manner. Blood (2007)
37. Casamayor-Palleja M., Khan M., and MacLennan I.C. A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. J Exp Med 181 (1995) 1293-1301
38. Kilinc M.O., Aulakh K.S., Nair R.E., et al. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 177 (2006) 6962-6973
39. Kim E.Y., Lee E.N., Lee J., et al. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation. Exp Mol Med 38 (2006) 284-294
40. van Kooten C. Immune regulation by CD40-CD40-l interactions - 2; Y2K update. Front Biosci 5 (2000) D880-693
41. Tomihara K., Kato K., Masuta Y., et al. Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated anti-tumor effects against human carcinoma cells. Int J Cancer 120 (2007) 1491-1498
42. Loskog A., and Totterman T.H. CD40L - a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 7 (2007) 23-28
43. Hunter T.B., Alsarraj M., Gladue R.P., Bedian V., and Antonia S.J. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumor T-cell responses in an in vitro mixed autologous tumor cell/lymph node cell model. Scand J Immunol 65 (2007) 479-486
44. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184 (1996) 747-752
45. Georgopoulos N.T., Steele L.P., Thomson M.J., Selby P.J., Southgate J., and Trejdosiewicz L.K. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 13 (2006) 1789-1801
46. Georgopoulos N.T., Merrick A., Scott N., Selby P.J., Melcher A., and Trejdosiewicz L.K. CD40-mediated death and cytokine secretion in colorectal cancer: A potential target for inflammatory tumor cell killing. Int J Cancer (2007)
47. Tong A.W., Papayoti M.H., Netto G., et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 7 (2001) 691-703
48. von Leoprechting A., van der Bruggen P., Pahl H.L., Aruffo A., and Simon J.C. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59 (1999) 1287-1294
49. De L.K.T., Whiting C.V., and Bland P.W. Proinflammatory cytokine synthesis by mucosal fibroblasts from mouse colitis is enhanced by interferon-gamma-mediated up-regulation of CD40 signalling. Clin Exp Immunol 147 (2007) 313-323
50. Conrad R., Remberger M., Cederlund K., et al. Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer. Biol Blood Marrow Transplant 12 (2006) 346-354
51. Eksioglu E.A., Mahmood S.S., Chang M., and Reddy V. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol (2007)
52. Reddy V., Iturraspe J.A., Tzolas A.C., Meier-Kriesche H.U., Schold J., and Wingard J.R. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood 103 (2004) 4330-4335
53. Reddy V., Winer A.G., Eksioglu E., Meier-Kriesche H.U., Schold J.D., and Wingard J.R. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 1014-1021
54. Dessureault S., Noyes D., Lee D., et al. Ann Surg Oncol 14 (2007) 869-884
55. Dillman R.O., Soori G., DePriest C., et al. Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a phase II trial of the cancer biotherapy research group. Cancer Biother Radiopharm 18 (2003) 727-733
56. Osada S., Imai H., Tomita H., et al. Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol 95 (2007) 491-498